The Scottish Medicines Consortium (SMC) is unable to recommend the use of lapatinib (Tyverb ™) 250 mg film-coated tablets within NHS Scotland for the treatment of metastatic breast cancer in postmenopausal women as the holder of the marketing authorisation has not made a submission.